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Abstract We report the first patient experiences with the
CardioMEMS device in the Erasmus MC Thorax Center
in the Netherlands. In line with clinical trial evidence, the
device is applicable in patients with chronic heart failure
in functional New York Heart Association class III with at
least 1 admission for heart failure in the past 12 months.
CardioMEMS has been shown to be safe and reliable, and
effective in reducing the number of hospitalisations for
heart failure by guided therapy based on pulmonary artery
pressures.
Keywords Heart failure · CardioMEMS ·
Telemonotoring · Remote monitoring · Individualized
therapy
Case/patient demonstration
We present a case of a 59-year-old male patient with
a history of diabetes mellitus and an anterolateral myocar-
dial infarction in March 2016 for which a percutaneous
coronary intervention (PCI) of the left anterior descending
artery and left circumflex artery was performed. Initial
echocardiogram demonstrated a severely depressed left
ventricular function with an ejection fraction of 15% and
severe mitral insufficiency. The patient was decongested
with diuretics and treated with standard heart failure med-
ication according to guidelines. He developed low cardiac
output syndrome with prerenal renal insufficiency with
minor changes in angiotensin converting enzyme (ACE)
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inhibitor dosages and orthostatic symptoms. The balance
between stable heart failure, renal insufficiency and ade-
quate dosages of heart failure (HF) treatment was delicate
but finally achieved. We performed a Swan-Ganz right heart
catheterisation with no pulmonary hypertension and nor-
mal pulmonary capillary wedge pressure. At the outpatient
clinic, heart failure medications were titrated to maximum
tolerance. Due to development of dry cough, we switched
Ramipril to valsartan with relieve of cough but prerenal
renal insufficiency remained, with an estimated glomerular
filtration rate (eGFR) of 35–45. Six months later, follow-
up echocardiogram demonstrated a severely depressed left
ventricular function and signs of elevated right heart pres-
sures. Due to progressive renal insufficiency, we switched
valsartan to hydralazine and intensified isosorbide dinitrate
and diuretics. The patient’s functional New York Heart
Association (NYHA) class was III and a VO2max was
performed with a score of 16 ml/kg/min. At this stage, we
admitted the patient to examine the pulmonary hyperten-
sion. There were no options to increase diuretics as the
patient was euvolemic and suffered from prerenal moder-
ate renal insufficiency. Invasive Swan-Ganz measurement
confirmed the estimated pressures on echocardiogram with
a pulmonary artery (PA) systolic pressure of 87 and a PA
diastolic pressure of 34 (mean PA pressure 52 mm Hg). We
decided to offer the patient a new device (CardioMEMS)
to monitor his pulmonary pressures remotely with respect
to treatment alterations which were previously difficult to
achieve based on physical examination, weight and blood
values alone.
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Fig. 1 CardioMEMS implantation and data read-outs. a Pulmonary arteriography and implantation, b placing the CardioMEMS device over
the wire with dislodgement, c read-out overview of follow-up with the CardioMEMS pressure during medical interventions with daily pressure
feedback, d example of data read-out: pulmonary pressure read-out
Telemonitoring in heart failure patients with the
CardioMEMS device
The CardioMEMS device is an implantable wireless system
for continuous monitoring of PA pressures which has been
shown to be safe and reliable and clinically effective in re-
ducing HF associated hospitalisations in the CHAMPION
trial [1]. Complication rate of the implantations are low with
1.4% which is comparable to a regular right heart catheteri-
sation (approved by the Food and Drug Administration and
CE (Conformité Européene) marked). The rationale of the
device is to use a pressure-driven clinical strategy instead of
waiting for the development of weight gain and symptoms
of decompensation, which occur generally 1–2 weeks after
the rise in left ventricular filling pressures [1]. With pro-
gression of heart failure, initially only the filling pressure
will increase, leading to autonomic adaptations and changes
in intrathoracic impedance. After that stage, patients are re-
taining fluid and will eventually gain weight and develop
symptoms of congestion. This process takes about 2 weeks
and diuretics are used to counteract this process, which, if
that fails, will lead to HF hospitalisation. The rationale of
the CardioMEMS device is to measure those pressures and
act on elevated pressures before weight gain and symptoms
occur in order to prevent HF hospitalisation.
The CHAMPION trial included patients with chronic
heart failure NYHA class III, irrespective of left ventric-
ular ejection fraction and a previous HF hospitalisation.
The trial randomised 560 patients to wireless implantable
haemodynamic monitoring versus standard care alone. In
6 months, a significant reduction in hospitalisations for HF
was demonstrated compared with the control group (haz-
ard ratio 0.63; 95% confidence interval 0.52–0.77; p-value <
0.0001). Several centres in the Netherlands have been asked
to participate in a post-marketing surveillance programme
from Germany. The Erasmus Medical Center has performed
multiple procedures, so far successfully, with comparable
clinical outcome as presented by the example in this case.
CardioMEMS is currently only available in a study environ-
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ment and not available as standard care in the Netherlands,
nor is it covered by medical insurance.
In our patient, the CardioMEMS device was implanted
without complications (Fig. 1a and b). The pressure curves
of the device were identical to Swan-Ganz. Based on the
pressure curves, we titrated the hydralazine dose to 40 mg
t.i. d. and isosorbide dinitrate dose to 40 mg t.i. d. With
every adjustment in medication, the pulmonary pressures
decreased (see the trend curve in Fig. 1c). The patient re-
ceived instructions and training on how to obtain data from
the device and perform daily pressure measurements at
home (Fig. 1d). Under the guidance of pressure, the changes
in medication were performed with more confidence. Now,
after one month of guidance, the patient is feeling well, HF
is NYHA class IIb, with current pressures of 55/25 (35)
mm Hg and still dropping. No hospitalisations for HF oc-
curred. Renal function is stable with an eGFR of 45–50.
The mitral regurgitation decreased from moderate to light.
As pulmonary hypertension developed rather quickly in this
patient who initially had no elevated pressures, we are curi-
ous, but as yet do not known, how quickly he will respond
to treatment. However, the decreasing trend is reassuring.
We have tested for reversibility of pulmonary hypertension
with nitroglycerin at the catheterisation laboratory, which
was positive.
For the treating heart failure specialist, the immediate
feedback of pressure monitoring is a great step forward.
However, it does change the way we work and think at
the outpatient clinic. In the current study protocol, the pa-
tient performs daily pressure measurements and the cardi-
ologist receives immediate feedback on recorded pressures
with notifications based upon set thresholds. Each week,
the physician checks the trend of mean PA pressure ac-
cording to study protocol. The physician can react on the
weekly trend of PA pressures by adjusting the medication,
such as the dose of diuretics, nitrates or other vasodila-
tors. So, with this new feature of pressure-guided therapy,
the physician can provide immediate and truly individu-
alised and tailored therapy, instead of having to rely solely
on the information of the patient’s symptoms and weight.
The patients report a greater convenience and confidence
as they are monitored daily and they feel much more se-
cure now. Surely, an important psychological effect. With
more devices being implanted and more experience gained,
we must get a better understanding of the role these new
technologies will have in heart failure care pathways and
rewrite our heart failure clinic set-ups. Currently, the costs
of these new technologies are high and their clinical use
is limited to participation in post-approval studies. In the
near future, when more experience is gained (and the treat-
ment covered by medical insurance in the Netherlands),
individualised patient care via telemonitoring can change
the clinical practice for physicians, specialist heart failure
nurses and, most importantly, patients.
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